Invited Speaker 37th TROG Cancer Research Annual Scientific Meeting 2025

NRG-HN014 | TD 24.02: Randomized Phase III Trial of Peri-operative Immunotherapy with Response-adjusted Surgery versus Standard-of-Care (SOC) Surgery for Resectable Stage III/IV Cutaneous Squamous Cell (#35)

Danny Rischin 1
  1. Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

Content is not available at the time of publishing.